Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as
single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in
patients with multiple myeloma or lymphoma and to describe the influence of the modified
immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution
and chimerism.